● Recruiting
Phase III
Oncology
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
What is being tested: Setidegrasib, a KRAS inhibitor, combined with either mFOLFIRINOX or NALIRIFOX chemotherapy regimens in patients with metastatic pancreatic cancer to evaluate…
22 Sep 2026
NCT07409272